JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

JW (Cayman) Therapeutics Co. Ltd

JW Therapeutics is an independent biotech company focused on the development, production, and commercialization of cell immunotherapy products.

msh id	COM:JWTHERAPEUTICS
symbol	2.13K
name	JW (Cayman) Therapeutics Co. Ltd
homepage url	https://www.jwtherapeutics.com
country	CN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	398
crunchbase url	-
linkedin url	-
founders	-

market cap	97.27M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.04
growth cost of revenue	-0.02
growth depreciation and amortization	-
growth ebitda	0.2
growth ebitda ratio	0.33
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.22
growth gross profit	0.5
growth gross profit ratio	0.26

2126

COM:JWTHERAPEUTICS

JW Therapeutics

Last Close

1.36

21/11 07:52

Market Cap

755.92M

Beta: -

Volume Today

279.50K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	133.17M
cost of revenue	133.17M
depreciation and amortization	9.35M
ebitda	-69.45M
ebitda ratio	-2.89
eps	-0.26
eps diluted	-0.26
operating expenses	121.33M
operating income	-78.8M
operating income ratio	-3.28

accounts receivables	-
capital expenditure	-
cash at beginning of period	191.2M
cash at end of period	191.2M
inventory	4.81M
working capital ttm	1.17B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-